Drug Profile
Janagliflozin - Sihuan Pharmaceutical Holdings Group
Alternative Names: SGLT2 inhibitor - SihuanLatest Information Update: 07 Sep 2022
Price :
$50
*
At a glance
- Originator Sihuan Pharmaceutical Holdings Group
- Class Antihypercalcaemics
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 07 Sep 2022 Janagliflozin is still in phase-III trials for Type 2 diabetes mellitus (Combination therapy, Treatment-experienced) in China (PO, Tablet) (NCT03851432)
- 10 Jun 2019 Safety and efficacy data from clinical trials in healthy volunteers and Type 2 diabetes mellitus released by Sihuan Pharmaceutical
- 07 Jun 2019 Pharmacokinetics and adverse events data from two single and multiple dose studies in healthy volunteers presented at the 79th Annual Scientific Sessions of the American Diabetes Association (AAD-2019)